Healthcare Aug 31, 2022 08:30 PM (GMT+8)
Enitiatebio (Chinese: 启元生物) completed one hundred million of CNY （USD） in Series A financing round on August 31, 2022. This round was led by Momentum Venture (Chinese: 时节创投), followed by Taikun Fund (Chinese: 泰鲲基金), LPSCO (Chinese:临平国投) and Hangzhou Jintou Industrial Fund (Chinese:杭州金投产业基金). StartPointAdvisors (Chinese: 行远致同) acted as the exclusive financial advisor for this transaction.
Enitiatebio was co-founded by Viva Vision (Chinese: 维眸生物) and Betta Biomedical Industry Fund (Chinese: 贝达生物医药产业基金) at the end of 2020. The company was dedicated to developing innovative drugs for treating autoimmune diseases.
The competitors of the company include 3SBIONIC(Chinese: 三生制药), CarthroniX, and Angany.